Regarding the overall prognostic ability, promoter methylation of the NUPR1 gene displayed a high AUC of 0.802 (S.E. = 0.060, p < 0.001), indicating its ability to predict the prognosis of the GBM patients. This evidence concerns the gene NUPR1 and glioblastoma.